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Abstract
Mitochondrial mechanisms, particularly the release of
cytochrome c, play a role in the death of nerve and glial
cells in cerebral ischemia. We have currently investi-
gated whether BID, a proapoptotic molecule of the bcl-2
family and promoter of the release of cytochrome c is
expressed in the brain, activated by cerebral ischemia in
vivo, and contributes to ischemic cell death. We found
BID in the cytosol of mouse brain and of primary cultured
mouse neurons and showed that neuronal BID is a sub-
strate for caspase 8. BID was cleaved in vivo 4 h after
transitory occlusion of the middle cerebral artery. Fur-
ther, BID–/– mice had a significant attenuation of infarc-
tion (–67%) and significantly lower release of cyto-
chrome c (–41%). The findings indicate that the proapop-
totic molecule BID may contribute to the demise of nerve
cells from cerebral ischemia by release of cytochrome c
and activation of caspase.
Copyright © 2002 S. Karger AG, Basel
Introduction
Programmed cell death is a feature of chronic and
acute neurodegenerative diseases including Alzheimer’s
and Huntington’s disease, amyotrophic lateral sclerosis
(ALS), and stroke [1, 2]. It is mediated, in part, by cas-
pases, a family of cysteine proteases that cleave and disas-
semble proteins essential for cell survival [3]. Caspases are
activated during cerebral ischemia [4–6], and ischemic
cell death is significantly attenuated by caspase inhibition
[7] or caspase gene deletion [8].
The sequence of events leading to caspase activation
has been well characterized in non-neuronal cells [9]. In
these cells, BID, a 22-kDa cytosolic member of the Bcl-2
family of proapoptotic proteins [10] provides one mecha-
nism by which TNF/Fas family death receptor activation
is linked to downstream events [11]. These death recep-
tors activate caspase 8, which cleaves BID to its truncated
active form (tBID; 15 kDa)[12]. tBID targets the outer
mitochondrial membrane and induces conformational
changes in BAK and BAX [13] and by so doing, triggers
cytochrome c release into the cytosol [14]. There cyto-
chrome c together with APAF-1 and caspase 9 form the
apoptosome complex, which results in activation of cas-
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pase 3 and other effector caspases and ultimately cause
cell death [15]. The importance of BID in death receptor
mediated programmed cell death and in amplification of
upstream cell death signals is demonstrated by the fact
that BID knockout mice are strongly resistant to death
receptor induced hepatocellular apoptosis [16].
Very little is known about BID expression and its role
in brain, or in fact, whether a similar death pathway
involving BID exists in neurons. However, expression of
cell surface death receptors of the TNF/Fas family [17–
19], cleavage of caspase 8 [5] and caspase 3 [6], and
release of cytochrome c from mitochondria [20], have all
been described individually in ischemia. Given these sim-
ilarities, we hypothesized that BID may figure as a media-
tor upstream of mitochondria in neuronal death after
cerebral ischemia. To explore this hypothesis, we used a
well-characterized model of ischemic cell death (middle
cerebral artery occlusion, MCAo). We determined wheth-
er BID knockout mice were protected against ischemia,
and examined the relationship between the presence of
activated BID (tBID) and cytochrome c release in adult
mouse brain.
Part of the original findings of this study have already
been published elsewhere [21].
Methods
Cytosolic and Mitochondrial Proteins
Tissues from adult C57Bl/6 mice (20–25 g) were homogenized in
10 volumes of hypertonic buffer [22]. Supernatants containing cyto-
solic proteins were isolated by centrifugation at 20,000 g. tBID was
enriched by immunoprecipitation (150 Ìg protein incubated with
anti-BID/tBID antibody at 1:500 dilution over night). All procedures
were performed at 4°C.
Western Blot
10–20 Ìg protein/lane were separated and blotted as previously
described [23]. The blot was probed with anti-Bid (rabbit polyclonal,
1:1,000), or anti-cytochrome c (clone 7H8.2C12, 1:200, BD Phar-
Mingen, Franklin Lakes, N.J., USA) at 4°C overnight. Membranes
were then exposed to horseradish-peroxidase-conjugated anti-rabbit
IgG for 1 h. Antibody binding was detected using the ECL system
(Amersham, Arlington Heights, IL). Equal protein loading of gels was
assured by Coomassie Blue or ·-tubulin staining. Relative optical
density of protein bands was quantitated by using the Bio-Rad Multi-
Analist Version 1.0
Transgenic Mice
BID-deficient mice (BID–/–) were generated as previously de-
scribed [16] and backcrossed 7–8 generations into its C57Bl/6 back-
ground strain. BID–/– mice were born at the expected Mendelian fre-
quency and showed no apparent developmental abnormalities. As
controls wild type animals (BID+/+) from the same litter (‘litter-
mates’) were used for all experiments. The macro- and microscopic
brain morphology of uninjured BID–/– mice did not differ from wild
type controls. Only male mice matched for age (6 weeks) and weight
(20–25 g) were used for experiments.
Transitory Focal Cerebral Ischemia
Cerebral ischemia was induced by an intraluminal filament as
previously described [24]. Successful occlusion and reperfusion was
demonstrated by Laser-Doppler flowmetry (PF2B; Perimed, Stock-
holm, Sweden) in each animal. Functional outcome was assessed on a
5-point scale (0 = no deficit, 1 = weakness of the contralateral fore-
paw, 2 = circling, 3 = loss of righting reflex, 4 = no motor activity).
Cytochrome c Assay
Cytochrome c in cytosolic fractions of brain homogenates was
measured by an ELISA system specific for mouse cytochrome c
(R&D Systems, Minneapolis, Minn., USA). Homogenates were pre-
pared from an equivalent lesioned area (striatum) in both strains.
Results are expressed as ng cytochrome c/mg protein. Values ob-
tained from the non-ischemic hemisphere were subtracted from the
values for the ischemic hemisphere in order to obtain a measure for
cytochrome c release specific to ischemia. The cytosolic origin of the
samples was proven by the fact that cytochrome oxidase, a mitochon-
drial protein, was not detected in these brain fractions (data not
shown).
Statistical Analysis
Data are presented as mean B SEM. All statistical analyses were
made with the SigmaStat 2.0 software package (Jandel Scientific,
Erkrath, Germany). For comparison between WT and BID–/– groups
the Mann-Whitney Rank Sum test was used. p ! 0.05 was considered
statistically significant.
Results
Expression of BID in the Brain
We characterized BID expression by demonstrating its
presence in brain. A 22-kDa band corresponding to BID
was observed in murine whole brain homogenates (n = 2).
The 22-kDa band was absent in homogenates from BID–/–
mice (n = 2; fig. 1).
Activation of BID after Cerebral Ischemia
In wild type mice, we demonstrated by Western Blot
analysis that BID was cleaved to its 15-kDa active frag-
ment (tBID) 2 h following 2 h of middle cerebral artery
occlusion (fig. 2).
Protection in BID–/– Mice after Focal Cerebral
Ischemia
In order to investigate if BID mediates ischemic cell
death, BID–/– and wild-type littermate mice were sub-
jected to 30 min of middle cerebral artery occlusion and
48 h of reperfusion. Blood flow distal to the occlusion
dropped below 20% in the two groups and returned to
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Fig. 1. BID is expressed in mouse brain. Mouse (C57B/6) brain
homogenate was probed for BID with a rabbit polyclonal antibody
(Western blotting). A 22-kDa band was detected which corresponds
to recombinant mouse BID [12]. This band was not detected in brain
homogenate from BID–/– mice (n = 3). From [21].
Fig. 3. Ischemic damage is reduced in BID–/– mice. Infarct volume
was reduced by 67% in BID–/– mice as compared to wild type mice
(n = 8 per group; * p ! 0.01) after 30 min middle cerebral artery
occlusion and 48 h reperfusion. From [21].
Fig. 2. BID cleavage after focal ischemia. Two hours after 2 h of
MCAo, brain homogenates from the ischemic (I) and contralateral
hemisphere were subjected to immunoprecipitation with an anti-
tBID antibody followed by Western blot analysis. tBID obtained by
incubation of recombinant BID with recombinant active caspase 8
was used as positive control (tBID) (n = 2). From [21].
Fig. 4. Cytochrome c release after focal ischemia. Following isch-
emia, 41% less cytochrome c was measured by ELISA in the cytosol
of BID–/– mice (n = 4) as compared to wild type littermates (n = 4;
* p ! 0.03). From [21].
pre-occlusion levels after recirculation. The mean infarct
volume was 67% smaller in BID–/– mice (55.5 B 29.0
mm3 and 18.3 B 6.4 mm3 in wild type and mutant,
respectively; n = 8 per group; p ! 0.002; fig. 3). In wild
type animals, the lateral striatum and the adjacent cere-
bral cortex showed extensive ischemic injury, while the
cortex was spared in BID–/– mice. Animals had only slight
neurological deficits 24 and 48 h after ischemia (0.4 B
0.2) and there was no difference between groups. Follow-
ing ischemia, brain edema was minimal and did not differ
between groups: the volumes of the ischemic hemispheres
were 102 B 3% and 104 B 5% of the contralateral hemi-
spheres in wild type and mutants, respectively.
Cytochrome C Release in BID–/– Mice after Focal
Cerebral Ischemia
Next we investigated whether BID was part of apoptot-
ic signaling pathways in vivo by comparing the levels of
cytosolic cytochrome c in homogenates of ischemic brains
from wild type and BID–/– mice subjected to 2 h of
MCAo. A significant reduction (–41%) was found in the
mutant brain by an ELISA method (3.9 B 1.1 vs. 6.6 B
1.1 ng/mg protein for mutant and wild type, respectively,
n = 4; p ! 0.03; fig. 4). As an important precondition to
interpreting these experiments, we verified that there
were no pre-morbid differences between wild type and
BID–/– groups in brain volume, vascular anatomy, resting
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absolute blood flow (209 B 24 vs. 220 B 17 ml/100 g/min
in wild type and mutants, respectively), or overt behav-
ior.
Phenotypes of BID–/– Mice
Macroscopically we observed no differences in brain
size or weight, or differences in histology (HE and cresyl
violet) between mutants and wild type strains. There were
no differences in numbers of neurons when other sites like
superior cervical ganglia and facial nerve nucleus were
counted (Korsmeyer, pers. commun.). The BID–/– mice
show no other obvious abnormal neuronal phenotypes
and the development of neuronal lineages is apparently
normal [16].
Discussion
We established that BID is a critical mediator of isch-
emic cell death within the central nervous system. We
observed reduced ischemic brain injury in mice with dele-
tion of the BID gene (fig. 3). We also found BID cleavage
in ischemic brain after ischemia (fig. 2). Treatment with
caspase inhibitors attenuated cell death and tissue injury
after in vivo and in vitro ischemia [21, 22]. Hence, BID as
well as caspases are critical cell death mediators of isch-
emic brain injury.
In non-neuronal cells, caspase activation can occur via
a sequence of events known as type II death receptor sig-
naling [25], in which stimulation of death receptors acti-
vates caspase 8. Caspase 8 in turn cleaves BID to tBID.
After migration to the mitochondrial membrane and
interaction with Bax tBID causes cytochrome c release
from mitochondria, which results in the activation of cas-
pase 3 and other caspases. Our data show that the molecu-
lar pathway for ischemic cell death in neurons resembles
the type II pathway. Caspase 8 is constitutively expressed
in brain and focal ischemia in vivo triggers activation of
caspase 8 [5]. We have evidence that caspase 8 cleaved
BID to tBID from brain homogenates [21]. Taken alto-
gether, it is likely that caspase 8 mediates BID cleavage in
the CNS as it is the cysteine protease with the strongest
BID-cleaving activity [12].
Regarding cytochrome c release, BID acts upstream of
both cytochrome c release and caspase-3 activation in
non-neuronal cells [12]. In the CNS, we found attenuated
cytochrome c release in ischemic striatum from BID–/–
mice following middle cerebral artery occlusion (fig. 4)
and less caspase 3 activation after oxygen glucose depriva-
tion in BID–/– cortical neurons [21]. In addition, BID
deletion reduces cytochrome c release, and protects
against fas-mediated liver injury [16] and against isch-
emia-induced CNS injury in vivo as shown in our present
study.
Despite strong evidence linking BID to pore formation
in the outer mitochondrial membrane, and to cytosolic
release of cytochrome c, cytochrome c release was not
completely abrogated in cells and tissues of BID–/– mice
(fig. 4). Release was apparently not caused by rupture of
mitochondrial membranes as we did not detect cyto-
chrome oxidase, a mitochondrial protein, in cytosolic
fractions at the same time (not shown). Our data suggest
that BID is not the sole mechanism for cytochrome c
release after cerebral ischemia. Other mechanisms and
molecules may contribute to the release process such as
unique mechanisms related to Bax, Bad, Bcl-2, Bcl-XL,
oxygen radicals, MnSOD, or opening of the mitochon-
drial permeability transition [26–29]. Furthermore, BCL-
2, and BCL-w modulate cytochrome c release and, for
example, an increase in their expression could protect tis-
sues from injury during ischemia [30, 31]. BID and other
mechanisms may also effect survival in non-neuronal cell
types (e.g., astrocytes, endothelial cells, microglia) which
were spared in ischemic BID–/– mouse brain. Further
work is necessary to clarify this point. Nevertheless, the
results generated using BID–/– mice convincingly demon-
strate a prominent role for BID in acute CNS injury.
Future strategies using gene therapy including dominant-
negative or anti-sense approach to eliminate BID may be
utilized to determine if they may help reduce brain injury
after cerebral ischemia.
In summary, BID promotes cell death in the brain fol-
lowing focal cerebral ischemia. Because BID is strategical-
ly located upstream of mitochondria and caspase 3 pro-
cessing [32], BID presents an attractive therapeutic target
for central nervous system diseases in which apoptotic cell
death is prominent.
Acknowledgments
This work was supported by grants from the Deutsche For-
schungsgemeinschaft (Pl 249/5-1 to NP) and the National Institutes
of Health (NS10828 and NS374141-02 to MAM).
Role of BID in Ischemic Cell Death Eur Surg Res 2002;34:37–41 41
References
1 Mattson MP: Apoptosis in neurodegenerative
disorders. Nature Rev Mol Cell Biol 2000;1:
120–129.
2 Yuan J, Yankner BA: Apoptosis in the nervous
system. Nature 2000;407:802–809.
3 Robertson GS, Crocker SJ, Nicholson DW,
Schulz JB: Neuroprotection by the inhibition
of apoptosis. Brain Pathol 2000;10:283–292.
4 Krajewski S, Krajewska M, Ellerby LM, Welsh
K, Xie Z, Deveraux QL, Salvesen GS, Brede-
sen DE, Rosenthal RE, Fiskum G, Reed JC:
Release of caspase-9 from mitochondria during
neuronal apoptosis and cerebral ischemia. Proc
Natl Acad Sci USA 1999;96:5752–5757.
5 Velier JJ, Ellison JA, Kikly KK, Spera PA,
Barone FC, Feuerstein GZ: Caspase-8 and cas-
pase-3 are expressed by different populations
of cortical neurons undergoing delayed cell
death after focal stroke in the rat. J Neurosci
1999;19:5932–5941.
6 Namura S, Zhu J, Fink K, Endres M, Srinivas-
an A, Tomaselli KJ, Yuan J, Moskowitz MA:
Activation and cleavage of caspase-3 in apopto-
sis induced by experimental cerebral ischemia.
J Neurosci 1998;18:3659–3668.
7 Hara H, Friedlander RM, Gagliardini V, Ayata
C, Fink K, Huang Z, Shimizu-Sasamata M,
Yuan J, Moskowitz MA: Inhibition of interleu-
kin 1 beta converting enzyme family proteases
reduces ischemic and excitotoxic neuronal
damage. Proc Natl Acad Sci USA 1997;94:
2007–2012.
8 Schielke GP, Yang GY, Shivers BD, Betz AL:
Reduced ischemic brain injury in interleukin-1
beta converting enzyme-deficient mice. J Cer-
eb Blood Flow Metab 1998;18:180–185.
9 Strasser A, O’Connor L, Dixit VM: Apoptosis
signaling. Annu Rev Biochem 2000;69:217–
245.
10 Wang K, Yin XM, Chao DT, Milliman CL,
Korsmeyer SJ, BID: A novel BH3 domain-only
death agonist. Genes Dev 1996;10:2859–2869.
11 Nagata S: BIDdable death. Nat Cell Biol 1999;
1:E143–E145.
12 Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID
by caspase 8 mediates the mitochondrial dam-
age in the Fas pathway of apoptosis. Cell 1998;
94:491–501.
13 Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer
SJ: Posttranslational N-myristoylation of BID
as a molecular switch for targeting mitochon-
dria and apoptosis. Science 2000;290:1761–
1765.
14 Wei MC, Lindsten T, Mootha VK, Weiler S,
Gross A, Ashiya M, Thompson CB, Korsmeyer
SJ: tBID, a membrane-targeted death ligand,
oligomerizes BAK to release cytochrome c.
Genes Dev 2000;14:2060–2071.
15 Zou H, Li Y, Liu X, Wang X: An APAF-1.cyto-
chrome c multimeric complex is a functional
apoptosome that activates procaspase-9. J Biol
Chem 1999;274:11549–11556.
16 Yin XM, Wang K, Gross A, Zhao Y, Zinkel S,
Klocke B, Roth KA, Korsmeyer SJ: BID-defi-
cient mice are resistant to Fas-induced hepato-
cellular apoptosis. Nature 1999;400:886–891.
17 Martin-Villalba A, Herr I, Jeremias I, Hahne
M, Brandt R, Vogel J, Schenkel J, Herdegen T,
Debatin KM: CD95 ligand (Fas-L/APO-1L)
and tumor necrosis factor-related apoptosis-
inducing ligand mediate ischemia-induced
apoptosis in neurons. J Neurosci 1999;19:
3809–3817.
18 Harrison DC, Roberts J, Campbell CA, Crook
B, Davis R, Deen K, Meakin J, Michalovich D,
Price J, Stammers M, Maycox PR: TR3 death
receptor expression in the normal and isch-
aemic brain. Neuroscience 2000;96:147–160.
19 Rosenbaum DM, Gupta G, D’Amore J, Singh
M, Weidenheim K, Zhang H, Kessler JA: Fas
(CD95/APO-1) plays a role in the pathophysi-
ology of focal cerebral ischemia. J Neurosci Res
2000;61:686–692.
20 Fujimura M, Morita-Fujimura Y, Murakami
K, Kawase M, Chan PH: Cytosolic redistribu-
tion of cytochrome c after transient focal cere-
bral ischemia in rats. J Cereb Blood Flow Me-
tab 1998;18:1239–1247.
21 Plesnila N, Le DA, Zinkel S, Amin-Hanjani S,
Qiu J, Chiarugi A, Thomas SS, Korsmeyer SJ,
Moskowitz MA: BID mediates cell death after
acute neurodegeneration induced by stroke and
oxygen-glucose deprivation. Proc Natl Acad
Sci USA 2001;98:15318–15323.
22 Chiarugi A and Moroni F: Effects of mitochon-
dria and o-methoxybenzoylalanine on 3-hy-
droxyanthranilic acid dioxygenase activity and
quinolinic acid synthesis. J Neurochem 1999;
72:1125–1132.
23 Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L,
Hirt L, Waeber C, Hyman BT, Yuan J, Mosko-
witz MA: Fas receptor and neuronal cell death
after spinal cord ischemia. J Neurosci 2000;20:
6879–6887.
24 Huang Z, Huang PL, Panahian N, Dalkara T,
Fishman MC, Moskowitz MA: Effects of cere-
bral ischemia in mice deficient in neuronal nit-
ric oxide synthase. Science 1994;265:1883–
1885.
25 Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li
F, Tomaselli KJ, Debatin KM, Krammer PH,
Peter ME: Two CD95 (APO-1/Fas) signaling
pathways. EMBO J 1998;17:1675–1687.
26 Fujimura M, Morita-Fujimura Y, Noshita N,
Sugawara T, Kawase M, Chan PH: The cyto-
solic antioxidant copper/zinc-superoxide dis-
mutase prevents the early release of mitochon-
drial cytochrome c in ischemic brain after tran-
sient focal cerebral ischemia in mice. J Neuro-
sci 2000;20:2817–2824.
27 Siesjo BK, Elmer E, Janelidze S, Keep M, Kris-
tian T, Ouyang YB, Uchino H: Role and mech-
anisms of secondary mitochondrial failure.
Acta Neurochir Suppl (Wien) 1999;73:7–13.
28 Fiskum G, Murphy AN, Beal MF: Mitochon-
dria in neurodegeneration: Acute ischemia and
chronic neurodegenerative diseases. J Cereb
Blood Flow Metab 1999;19:351–369.
29 Springer JE, Azbill RD, Nottingham SA, Ken-
nedy SE: Calcineurin-mediated BAD dephos-
phorylation activates the caspase-3 apoptotic
cascade in traumatic spinal cord injury. J Neu-
rosci 2000;20:7246–7251.
30 Martinou JC, Dubois-Dauphin M, Staple JK,
Rodriguez I, Frankowski H, Missotten M, Al-
bertini P, Talabot D, Catsicas S, Pietra C:
Overexpression of BCL-2 in transgenic mice
protects neurons from naturally occurring cell
death and experimental ischemia. Neuron
1994;13:1017–1030.
31 Yan C, Chen J, Chen D, Minami M, Pei W,
Yin XM, Simon RP: Overexpression of the cell
death suppressor Bcl-w in ischemic brain: Im-
plications for a neuroprotective role via the
mitochondrial pathway. J Cereb Blood Flow
Metab 2000;20:620–630.
32 Fink K, Zhu J, Namura S, Shimizu-Sasamata
M, Endres M, Ma J, Dalkara T, Yuan J, Mos-
kowitz MA: Prolonged therapeutic window for
ischemic brain damage caused by delayed cas-
pase activation. J Cereb Blood Flow Metab
1998;18:1071–1076.
